Lawrence Lynn v. Becton, Dickinson & Co.

CourtCourt of Appeals for the Sixth Circuit
DecidedFebruary 6, 2024
Docket23-3214
StatusUnpublished

This text of Lawrence Lynn v. Becton, Dickinson & Co. (Lawrence Lynn v. Becton, Dickinson & Co.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lawrence Lynn v. Becton, Dickinson & Co., (6th Cir. 2024).

Opinion

NOT RECOMMENDED FOR PUBLICATION File Name: 24a0056n.06

No. 23-3214

UNITED STATES COURT OF APPEALS FILED FOR THE SIXTH CIRCUIT Feb 06, 2024 KELLY L. STEPHENS, Clerk ) LAWRENCE A. LYNN, ) Plaintiff-Appellant, ) ON APPEAL FROM THE UNITED v. ) STATES DISTRICT COURT FOR ) THE SOUTHERN DISTRICT OF BECTON, DICKINSON & CO., ) OHIO Defendant-Appellee. ) OPINION ) _______________________________________)

Before: COLE, GILMAN, and LARSEN, Circuit Judges.

RONALD LEE GILMAN, Circuit Judge. In 1998, Dr. Lawrence Lynn and Becton,

Dickinson & Co. (BD) contracted for BD to license several patents owned by Lynn. The parties

amended their Patent License Agreement twice thereafter and, as relevant to this appeal, those

amendments addressed the duration of the license and the amount of royalties that BD owed Lynn.

Based on BD’s belief that the License Agreement ended on August 12, 2019, it stopped paying

royalties to Lynn after that date. But Lynn contends that royalty payments under the License

Agreement extended until at least December 7, 2021, so he sued BD in federal court, alleging

breach of contract and breach of the implied duty of good faith and fair dealing.

The district court granted summary judgment in favor of BD, concluding that BD’s

obligation to pay royalties to Lynn ended on August 12, 2019. It also concluded that Lynn had

failed to establish a genuine dispute of material fact regarding the amount of royalties that BD was

obligated to pay him. As a result, the court granted summary judgment to BD on all of Lynn’s

claims. No. 23-3214, Lynn v. Becton, Dickinson & Co.

Lynn now appeals. He asserts that the district court erred in (1) interpreting the provision

of the License Agreement governing the end date for the payment of royalties, and (2) concluding

that the evidence he provided was insufficient to establish a genuine dispute of material fact as to

the amount of royalties due him. Because we conclude that none of Lynn’s arguments has merit,

we AFFIRM the judgment of the district court.

I. BACKGROUND

A. The parties and their agreement

Lynn is a physician who has invented several medical devices, including a class of devices

known as Blunt Cannula Penetration Medical Valves (the Valves). He owns several patents

relating to the Valves, which are used to facilitate the delivery of medication to patients through

an intravenous system. BD is a global technology company that develops, manufactures, and sells

a variety of medical supplies and devices.

The License Agreement granted BD the exclusive right to several of Lynn’s patents and

patent applications, including “any continuations, continuations in part, divisions, extensions,

substitutions, reissues or reexaminations thereof, and all patents issuing therefrom; and any

subsequently filed patent applications, and any patents issuing therefrom owned by or assigned to

Dr. Lynn which claim [the Valves].” In exchange, BD agreed to pay royalties to Lynn for sales of

“Royalty Bearing Products,” which the License Agreement defined as

any Blunt Cannula Penetration Medical Valve (1) whose manufacture, use, sale, offer for sale, or importation by BD or a Sublicensee, but for this Agreement, in a jurisdiction where a Valid Claim, as defined below, exists, would infringe, induce infringement of, or constitute contributory infringement of such a Valid Claim, and/or (2) which falls within the scope of the disclosures or claims of any patent applications included in the Licensed Patents, and/or (3) which falls within the scope of a pending patent application or patent of any improvement thereto which is made or has been made by BD prior to the end of three years after the First Commercial Sale.

2 No. 23-3214, Lynn v. Becton, Dickinson & Co.

The Royalty Bearing Product at issue here is BD’s Q-SyteTM (the Q-Syte), a needle-free

connector that helps reduce the risk of accidental needle-stick injuries to healthcare workers.

Under the original License Agreement, BD’s obligation to pay royalties would end “[a]t the

expiration of the last to expire patent under the Licensed Patents having a Valid Claim covering

Royalty Bearing Products.” (Although BD disputes whether the Q-Syte is a qualifying Royalty

Bearing Product under the parties’ Licensing Agreement, we need not address this argument

because we affirm the district court’s grant of summary judgment in BD’s favor on other grounds).

In February 2005, the parties amended the License Agreement to adjust the royalties

payable to Lynn. As relevant here, this First Amendment stated as follows:

The royalty amounts set forth in this Exhibit A will be adjusted each Fiscal Year by an amount equal to 50% of the change, if any, during the prior Fiscal Year in the Consumer Price Index — All Urban Consumers promulgated by the U.S. Department of Labor, or any successor index.

In March 2007, Lynn filed a patent application that was published as patent application

number 20070225635 (the ’635 Application). Two months later, Lynn filed patent application

number 11/801,649, which both parties refer to as the ’649 Application. The ’649 Application

was a “continuation-in-part” of the ’635 Application and another patent application. For reference,

§ 201.08 of the Manual of Patent Examining Procedure states that “[a] continuation-in-part is an

application filed during the lifetime of an earlier nonprovisional application, repeating some

substantial portion or all of the earlier nonprovisional application and adding matter not disclosed

in the earlier nonprovisional application.”

In February 2008, when both the ’635 and the ’649 Applications were still pending, the

parties amended the License Agreement once again. One of the sections of this Second

Amendment provided that, subject to certain exceptions, BD “shall have no further obligation to

Dr. Lynn under the Licensed Patents or Technical Information as of August 12, 2019.” The Second

3 No. 23-3214, Lynn v. Becton, Dickinson & Co.

Amendment also clarified which patents were “Licensed Patents” under the License Agreement,

utilizing the following language:

For clarity, and not for the purpose of limitation, Licensed Patents shall include all Blunt Cannula Penetration Medical Valve patent applications or patents, filed by BD or Dr. Lynn and Dr. Lynn’s interest in such patent applications or patents that are jointly owned with BD that are filed or granted after of [sic] the effective date of this Second Amendment. The parties agree that Licensed Patents shall not include applications and patents which claim swab pouches, swabs and protectors for luer valves, and/or swab pouch related methods for swabbing and protecting luer valves including, without limitation, patent applications nos. 20080039803, 20080038167, and 20070225660 and provisional application 61062976 or subsequently filed applications or patents including foreign counterparts claiming these inventions.

In June 2009, the United States Patent and Trademark Office (the Patent Office) deemed

the ’635 Application abandoned after Lynn failed to “timely file a proper reply” to the Patent

Office’s October 2008 Non-Final Rejection letter. No patent ever issued directly from the ’635

Application itself, but in July 2013, U.S. Patent No. 8,480,968 (the ’968 Patent) issued directly

from the ’649 Application, which is a continuation-in-part of the ’635 Application.

On August 12, 2019, BD stopped making royalty payments to Lynn. Almost a year and a

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cooper Technologies Co. v. Dudas
536 F.3d 1330 (Federal Circuit, 2008)
Glaxo, Inc., and Glaxo Group Limited v. Novopharm, Ltd.
110 F.3d 1562 (Federal Circuit, 1997)
Fernando Tatis v. Us Bancorp
473 F.3d 672 (Sixth Circuit, 2007)
Janice Gecewicz v. Henry Ford Macomb Hospital Cor
683 F.3d 316 (Sixth Circuit, 2012)
Arcelormittal France v. Ak Steel Corp.
700 F.3d 1314 (Federal Circuit, 2012)
Alexander v. CareSource
576 F.3d 551 (Sixth Circuit, 2009)
Nautilus, Inc. v. Biosig Instruments, Inc.
134 S. Ct. 2120 (Supreme Court, 2014)
Sauer v. Crews (Slip Opinion)
2014 Ohio 3655 (Ohio Supreme Court, 2014)
Feldkamp v. Usaa Insurance Company
743 N.E.2d 405 (Ohio Court of Appeals, 2000)
Dall Motor Parts Co. v. Packard Motor Car Co.
178 N.E. 835 (Ohio Supreme Court, 1931)
Lutz v. Chesapeake Appalachia, L.L.C. (Slip Opinion)
2016 Ohio 7549 (Ohio Supreme Court, 2016)
Nanika Wilkerson v. Am. Family Ins. Co.
997 F.3d 666 (Sixth Circuit, 2021)
Timothy Boykin v. Family Dollar Stores of Mich.
3 F.4th 832 (Sixth Circuit, 2021)
P.I. & I. Motor Express, Inc. v. RLI Ins. Co.
40 F.4th 398 (Sixth Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
Lawrence Lynn v. Becton, Dickinson & Co., Counsel Stack Legal Research, https://law.counselstack.com/opinion/lawrence-lynn-v-becton-dickinson-co-ca6-2024.